Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, H2 2016’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)

The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ariad Pharmaceuticals, Inc.

AstraZeneca Plc

Bayer AG

Celon Pharma Sp. z o.o.

Pfizer Inc.

Sareum Holdings Plc

Seattle Genetics, Inc.

Teva Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anaplastic Large Cell Lymphoma (ALCL) Overview 7

Therapeutics Development 8

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 8

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 9

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 13

Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 14

Ariad Pharmaceuticals, Inc. 14

AstraZeneca Plc 15

Bayer AG 16

Celon Pharma Sp. z o.o. 17

Pfizer Inc. 18

Sareum Holdings Plc 19

Seattle Genetics, Inc. 20

Teva Pharmaceutical Industries Ltd. 21

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

AdIL-24 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

AZD-3463 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

brentuximab vedotin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

brigatinib - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CEP-37440 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

copanlisib hydrochloride - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

crizotinib - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

SAR-3 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

SAR-4 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

SH-7129 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 81

Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products 82

Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 83

Featured News & Press Releases 83

Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 83

Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma 84

Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 85

Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 87

Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 89

Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 91

Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 92

Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 93

Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 93

Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 94

Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 96

Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 98

May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA 99

Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan 100

Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL 101

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 103

Disclaimer 104

List of Tables

List of Tables

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 14

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by AstraZeneca Plc, H2 2016 15

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Bayer AG, H2 2016 16

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Celon Pharma Sp. z o.o., H2 2016 17

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Pfizer Inc., H2 2016 18

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Sareum Holdings Plc, H2 2016 19

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Seattle Genetics, Inc., H2 2016 20

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Anaplastic Large Cell Lymphoma (ALCL) – Dormant Projects, H2 2016 81

Anaplastic Large Cell Lymphoma (ALCL) – Discontinued Products, H2 2016 82

List of Figures

List of Figures

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Top 10 Targets, H2 2016 23

Number of Products by Stage and Top 10 Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports